Biapenem

Drug Profile

Biapenem

Alternative Names: CL 186815; L 627; LJC 10627; Omegacin

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Meiji Seika Pharma; Wyeth
  • Class Antibacterials; Carbapenems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 31 Jan 2003 Discontinued - Preclinical for Bacterial infections in Europe (IV)
  • 30 Jan 2003 Discontinued - Phase-II for Bacterial infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top